CDK4/6 Extends Reach Into Early-Stage Breast Cancer
(MedPage Today) -- CHICAGO -- Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) in patients with early-stage, high-risk breast cancer and hormone receptor (HR)-positive/HER2...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hematology | HER2 | Hormones